Real-World PSA Progression After Enzalutamide or Abiraterone for Metastatic CRPC
Dec 19, 2023
A real-world study presented at the virtual 2021 ASCO Annual Meeting evaluated prostate-specific antigen pattern progression and its association with overall survival (OS) among patients with metastatic castration-resistant prostate cancer (CRPC) who were treated with enzalutamide or abiraterone. In a real-world setting, prostate-specific antigen value is used among practitioners to monitor treatment outcomes in patients with metastatic CRPC, however, due to possible spurious “flare” reactions, early prostate-specific antigen changes are not accounted for in the definition of prostate-specific antigen progression.
Radiation Oncologists Met With Congressional Leaders to Reverse CMS Cuts and Provide Equal Access to Care
Radiation oncologists met with Congress to urge leaders to consider how the Medicare and Medicaid Services (CMS) proposal to make significant cuts to radiation oncology facilities could be detrimental to the survival of patients with Read more…
FDA Approves Neoadjuvant Pembrolizumab Combination for Early TNBC Indication
The FDA granted approval to the supplemental biologics license application (sBLA) for pembrolizumab (Keytruda) as neoadjuvant therapy for patients with high-risk early-stage triple-negative breast cancer (TNBC) when given in combination with chemotherapy followed by single-agent Read more…
Recommended TVUS Screening Thresholds May Miss Endometrial Cancer in Black Women
Adherence to current clinical guidelines for the evaluation of postmenopausal bleeding may result in systematic underdiagnosis of endometrial cancer (EC) in Black women, according to a study published online July 15 in JAMA Oncology. Kemi M. Read more…